← FDA DRUG APPROVALS

FDA NDA · NDA218571

CARDAMYST

etripamil

Sponsor: MILESTONE PHARMS USA

APPLICATION
NDA218571
TYPE
NDA
ORIGINAL APPROVAL
2025-12-12
LATEST ACTION
2025-12-12
ROUTE
NASAL
DOSAGE FORM
SPRAY
MARKETING STATUS
Prescription

Products

CARDAMYST · ReferencePrescription
ETRIPAMIL 70MG · SPRAY · NASAL

Approval history

2025-12-12Type 1 - New Molecular Entity · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →